VIRI Stock Price, Virios Therapeutics, LLC Quote, Chart

Market Summary

USD0.35-0.04

Market Closed

-10.26%

VIRI Stock Price

View Fullscreen

VIRI RSI Chart

VIRI Valuation

Market Cap

6.7M

Price/Earnings (Trailing)

-1.33

EV/EBITDA

-0.88

Price/Free Cashflow

-1.64

MarketCap/EBT

-1.33

VIRI Price/Earnings (Trailing)

VIRI Profitability

Return on Equity

-191.01%

Return on Assets

-157.24%

Free Cashflow Yield

-60.97%

VIRI Fundamentals

VIRI Earnings

Earnings (TTM)

-5.1M

Earnings Growth (Yr)

14.87%

Earnings Growth (Qtr)

-17.06%

Breaking Down VIRI Revenue

Last 30 days

-22.2%

Last 90 days

-7.9%

Trailing 12 Months

-68.2%

How does VIRI drawdown profile look like?

VIRI Financial Health

Current Ratio

5.66

VIRI Investor Care

Shares Dilution (1Y)

5.06%

Diluted EPS (TTM)

-0.27

Tracking the Latest Insider Buys and Sells of Virios Therapeutics, LLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 21, 2023	pridgen william	bought	19,992	1.3037	15,335	-
Aug 17, 2023	duncan gregory scott	bought	31,245	1.2498	25,000	chief executive officer
Dec 08, 2022	whitley richard james	sold	-466	0.2591	-1,800	-
May 23, 2022	walsh angela	bought	9,150	4.575	2,000	svp of finance
May 23, 2022	duncan gregory scott	bought	33,900	4.52	7,500	chief executive officer
May 18, 2022	whitley richard james	bought	2,262	4.525	500	-
May 18, 2022	pridgen william	bought	1,084	4.5	241	-
May 17, 2022	pridgen william	bought	58,913	4.3802	13,450	-
Mar 29, 2022	pridgen william	bought	2,964	4.9408	600	-
Mar 23, 2022	pridgen william	bought	12,001	5.4627	2,197	-

Which funds bought or sold VIRI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	8,144	8,144	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-5,066	25,310	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-1,438	7,187	-%
May 15, 2024	William Howard & Co Financial Advisors Inc	new	-	5,000	5,000	-%
May 15, 2024	Cetera Advisors LLC	reduced	-12.23	-2,095	5,702	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	1.6	-593	3,262	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	9,133	9,133	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	-2,305	11,515	-%
May 13, 2024	XTX Topco Ltd	sold off	-100	-13,087	-	-%

Are Funds Buying or Selling VIRI?

Are funds buying VIRI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VIRI

No. of Funds

Unveiling Virios Therapeutics, LLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	corday brian david	4.6%	882,400	SC 13G/A
Nov 14, 2023	corday brian david	6.84%	1,316,049	SC 13G/A
Jun 13, 2023	corday brian david	7.3%	1,327,051	SC 13G/A
May 15, 2023	corday brian david	7.1%	1,299,980	SC 13G/A
Mar 31, 2023	corday brian david	6.9%	1,263,198	SC 13G/A
Feb 14, 2023	masters capital management llc	0%	0	SC 13G/A
Feb 13, 2023	duncan gregory scott	2.7%	501,715	SC 13G/A
Feb 13, 2023	burch richard alan	2.4%	448,056	SC 13G/A
Feb 13, 2023	pridgen william	4.1%	753,819	SC 13G/A
Feb 13, 2023	ionic ventures, llc	3.80%	697,292	SC 13G/A

Recent SEC filings of Virios Therapeutics, LLC

View All Filings

Date Filed	Form Type	Document
May 17, 2024	424B4	Prospectus Filed
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Mar 08, 2024	10-K/A	Annual Report
Mar 06, 2024	8-K	Current Report
Mar 01, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report

Peers (Alternatives to Virios Therapeutics, LLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Virios Therapeutics, LLC News

Latest updates

Virios Therapeutics, LLC Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-22.6%	3,225	4,165	5,249	5,212	6,521	8,370	10,858	9,040	12,550	15,777	20,107	23,765	28,275	31,473
Current Assets	-22.6%	3,225	4,165	5,249	5,212	6,521	8,370	10,858	9,040	12,550	15,777	20,107	23,765	28,275	31,473
Cash Equivalents	-28.3%	2,380	3,317	4,786	4,590	5,333	7,031	9,788	7,695	11,352	14,008	19,186	21,835	24,586	29,795
Liabilities	59.0%	570	359	487	520	549	1,043	1,633	1,898	1,877	1,276	1,227	906	1,167	1,532
Current Liabilities	59.0%	570	359	487	520	549	1,043	1,633	1,898	1,877	1,276	1,227	906	1,167	1,532
Shareholder's Equity	-30.3%	2,655	3,807	4,762	4,692	5,971	7,326	9,225	7,142	10,673	14,501	18,880	22,859	27,107	29,941
Retained Earnings	-2.1%	-62,760	-61,469	-60,366	-59,130	-57,690	-56,173	-54,128	-51,552	-47,885	-43,925	-39,414	-35,300	-31,000	-27,965
Additional Paid-In Capital	0.2%	65,712	65,573	65,425	64,113	63,660	63,498	63,352	58,694	58,558	58,426	58,294	58,162	58,128	57,905
Shares Outstanding	0%	19,258	19,258	19,258	18,330	18,330	18,330	9,200	8,330	8,330	8,330	8,330	8,328	-	-
Float	-	-	-	-	24,372	-	-	-	31,229	-	-	-	46,802	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	36.2%	-937	-1,469	-960	-742	-1,698	-2,671	-2,483	-3,657	-2,656	-5,178	-2,648	-2,750	-5,112	-2,286	-558	-772	-277
Share Based Compensation	-6.3%	139	148	148	162	162	150	164	137	132	132	132	34.00	25.00	-	-	-	-
Cashflow From Financing	-	-	-	-	-	-	-85.99	-	-	-	-	-	-	-97.60	31,583	9.00	627	1,163

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VIRI Income Statement

2024-03-31

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 343,717	$ 497,714
General and administrative expenses	970,384	1,059,573
Total operating expenses	1,314,101	1,557,287
Loss from operations	(1,314,101)	(1,557,287)
Other income:
Interest income	22,766	40,423
Total other income	22,766	40,423
Loss before income taxes	(1,291,335)	(1,516,864)
Net loss	$ (1,291,335)	$ (1,516,864)
Basic net loss per share (in dollars per share)	$ (0.07)	$ (0.08)
Diluted net loss per share (in dollars per share)	$ (0.07)	$ (0.08)
Weighted average number of shares outstanding - basic (in shares)	19,257,937	18,330,390
Weighted average number of shares outstanding - diluted (in shares)	19,257,937	18,330,390

VIRI Balance Sheet

2024-03-31

BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 2,379,532	$ 3,316,946
Prepaid expenses and other current assets	845,079	848,496
Total current assets	3,224,611	4,165,442
Total assets	3,224,611	4,165,442
Current liabilities:
Accounts payable	196,759	111,913
Accrued expenses	373,324	246,635
Total current liabilities	570,083	358,548
Total liabilities	570,083	358,548
Commitments and contingencies (Note 8)
Stockholders' equity:
Common stock, $0.0001 par value; 43,000,000 shares authorized; 19,450,888 and 19,257,937 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,926	1,926
Preferred stock, $0.0001 par value; 2,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023
Additional paid-in capital	65,712,269	65,573,300
Accumulated deficit	(62,760,557)	(61,469,222)
Stockholders' equity before treasury stock	2,953,638	4,106,004
Less: Treasury stock, 192,951 shares of common stock at cost	(299,110)	(299,110)
Total stockholders' equity	2,654,528	3,806,894
Total liabilities and stockholders' equity	$ 3,224,611	$ 4,165,442

About Virios Therapeutics, LLC

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

CEO	Mr. Gregory Duncan
WEBSITE	virios.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Virios Therapeutics, LLC Frequently Asked Questions

What is the ticker symbol for Virios Therapeutics, LLC? What does VIRI stand for in stocks?

VIRI is the stock ticker symbol of Virios Therapeutics, LLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Virios Therapeutics, LLC (VIRI)?

As of Fri May 17 2024, market cap of Virios Therapeutics, LLC is 6.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIRI stock?

You can check VIRI's fair value in chart for subscribers.

What is the fair value of VIRI stock?

You can check VIRI's fair value in chart for subscribers. The fair value of Virios Therapeutics, LLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Virios Therapeutics, LLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIRI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Virios Therapeutics, LLC a good stock to buy?

The fair value guage provides a quick view whether VIRI is over valued or under valued. Whether Virios Therapeutics, LLC is cheap or expensive depends on the assumptions which impact Virios Therapeutics, LLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIRI.